{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:36:35Z","timestamp":1770993395941,"version":"3.50.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cld.2020.07.011","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T19:09:53Z","timestamp":1601579393000},"page":"681-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Locoregional Therapies for Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Anjana A.","family":"Pillai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for hepatocellular carcinoma: current best practice and future direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2020.07.011_bib2","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","author":"Llovet","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2020.07.011_bib3","doi-asserted-by":"crossref","first-page":"4756147","DOI":"10.1155\/2018\/4756147","article-title":"Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery","volume":"2018","author":"Shiina","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib4","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/hep.20465","article-title":"Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma","volume":"40","author":"Sala","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib5","first-page":"325","article-title":"Single hepatocellular carcinoma smaller than 2\u00a0cm: are ethanol injection and radiofrequency ablation equally effective?","volume":"35","author":"Pompili","year":"2015","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib6","first-page":"2291","article-title":"Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial","volume":"31","author":"Giorgio","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cld.2020.07.011_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-9-31","article-title":"Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma","volume":"9","author":"Bouza","year":"2009","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.12.004","article-title":"Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis","volume":"52","author":"Germani","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","article-title":"Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3\u00a0cm or less","volume":"54","author":"Lin","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A\u00a0randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"Shiina","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/00365520701885481","article-title":"Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial","volume":"43","author":"Brunello","year":"2008","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.22648","article-title":"Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies","volume":"49","author":"Cho","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.7150\/ijms.5.327","article-title":"Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis","volume":"5","author":"Salmi","year":"2008","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1148\/radiol.14132958","article-title":"Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update","volume":"273","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2013.04.009","article-title":"Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma","volume":"59","author":"Cucchetti","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/jgh.12441","article-title":"Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma","volume":"29","author":"Fang","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.cld.2020.07.011_bib17","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/bjs.10677","article-title":"Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma","volume":"104","author":"Ng","year":"2017","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4174\/astr.2018.94.2.74","article-title":"A\u00a0prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma","volume":"94","author":"Lee","year":"2018","journal-title":"Ann Surg Treat Res"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/00313020802579292","article-title":"A\u00a0comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver","volume":"41","author":"Bhardwaj","year":"2009","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1245\/ASO.2003.03.045","article-title":"Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis","volume":"10","author":"Wright","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/02656736.2015.1127434","article-title":"Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Facciorusso","year":"2016","journal-title":"Int J Hyperthermia"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4254\/wjh.v7.i8.1054","article-title":"Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"7","author":"Poulou","year":"2015","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1148\/radiol.2351031944","article-title":"Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation","volume":"235","author":"Liang","year":"2005","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/jgh.12088","article-title":"Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy","volume":"28","author":"Xu","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2020.07.011_bib25","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Diagn Interv Radiol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/hep.27548","article-title":"Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib27","first-page":"e4994","article-title":"Irreversible electroporation for liver tumors: a review of literature","volume":"11","author":"Tameez Ud Din","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2478\/raon-2019-0011","article-title":"Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors","volume":"53","author":"Verloh","year":"2019","journal-title":"Radiol Oncol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1148\/radiol.2017161413","article-title":"Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series","volume":"284","author":"Sutter","year":"2017","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib30","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jvir.2015.05.014","article-title":"Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis","volume":"26","author":"Cheng","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"10","key":"10.1016\/j.cld.2020.07.011_bib31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s00270-017-1692-3","article-title":"A\u00a0comparative study of ablation boundary sharpness after percutaneous radiofrequency, cryo-, microwave, and irreversible electroporation ablation in normal swine liver and kidneys","volume":"40","author":"Cornelis","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.21037\/jgo.2018.06.01","article-title":"Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions","volume":"9","author":"Lin","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib33","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2015.61.4925","article-title":"Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma","volume":"34","author":"Wahl","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"19","key":"10.1016\/j.cld.2020.07.011_bib35","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib36","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crad.2012.06.112","article-title":"Hepatic embolotherapy in interventional oncology: technology, techniques, and applications","volume":"68","author":"Kritzinger","year":"2013","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1148\/112.1.13","article-title":"Therapeutic transcatheter arterial embolization","volume":"112","author":"Tadavarthy","year":"1974","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/hep.1840200315","article-title":"Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials","volume":"20","author":"Bruix","year":"1994","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib40","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jvir.2008.02.013","article-title":"Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma","volume":"19","author":"Maluccio","year":"2008","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"9","key":"10.1016\/j.cld.2020.07.011_bib42","doi-asserted-by":"crossref","first-page":"e0184597","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Katsanos","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cld.2020.07.011_bib43","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/1097-0142(19861201)58:11<2386::AID-CNCR2820581105>3.0.CO;2-G","article-title":"Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study","volume":"58","author":"Kajanti","year":"1986","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib44","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T","article-title":"A\u00a0new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge","volume":"60","author":"Sasaki","year":"1987","journal-title":"Cancer"},{"issue":"5 Suppl 1","key":"10.1016\/j.cld.2020.07.011_bib45","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1053\/j.gastro.2004.09.032","article-title":"Chemoembolization for hepatocellular carcinoma","volume":"127","author":"Bruix","year":"2004","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib46","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"9319","key":"10.1016\/j.cld.2020.07.011_bib47","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib48","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib49","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1078-0432.CCR-05-2225","article-title":"New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer","volume":"12","author":"Hong","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"10.1016\/j.cld.2020.07.011_bib51","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000329602","article-title":"A\u00a0randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"34","author":"van Malenstein","year":"2011","journal-title":"Onkologie"},{"issue":"11","key":"10.1016\/j.cld.2020.07.011_bib52","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jvir.2011.07.002","article-title":"Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma","volume":"22","author":"Sacco","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"issue":"124","key":"10.1016\/j.cld.2020.07.011_bib54","first-page":"813","article-title":"Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis","volume":"60","author":"Gao","year":"2013","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib55","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.dld.2016.02.005","article-title":"Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis","volume":"48","author":"Facciorusso","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib56","first-page":"510","article-title":"Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis","volume":"17","author":"Zou","year":"2016","journal-title":"J\u00a0Dig Dis"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib57","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clinre.2016.05.013","article-title":"Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"41","author":"Chen","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hepr.12450","article-title":"Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma","volume":"45","author":"Xie","year":"2015","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib59","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/jgh.12439","article-title":"Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"29","author":"Huang","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"Suppl","key":"10.1016\/j.cld.2020.07.011_bib60","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/BF00687096","volume":"31","author":"Kawai","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.cld.2020.07.011_bib61","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO;2-4","article-title":"Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study","volume":"74","author":"Chang","year":"1994","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.cld.2020.07.011_bib62","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2015.64.0821","article-title":"Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone","volume":"34","author":"Brown","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib63","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clinre.2015.07.008","article-title":"Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"40","author":"Chen","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvir.2014.10.047","article-title":"Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation","volume":"26","author":"Ginsburg","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2020.07.011_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000481243","article-title":"Transarterial chemoembolization in combination with a molecular targeted agent: lessons learned from negative trials (post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)","volume":"93","author":"Kudo","year":"2017","journal-title":"Oncology"},{"issue":"4_suppl","key":"10.1016\/j.cld.2020.07.011_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.2018.36.4_suppl.206","article-title":"Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial","volume":"36","author":"Kudo","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib68","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","article-title":"Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"1","author":"Huo","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7 Suppl","key":"10.1016\/j.cld.2020.07.011_bib69","doi-asserted-by":"crossref","first-page":"S425","DOI":"10.1016\/j.jvir.2009.04.021","article-title":"Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria","volume":"20","author":"Brown","year":"2009","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib70","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2006.05.065","article-title":"Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma","volume":"66","author":"Sangro","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2020.07.011_bib71","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1148\/rg.25si055515","article-title":"Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications","volume":"25","author":"Murthy","year":"2005","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib73","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib74","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib75","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.cld.2020.07.011_bib76","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","article-title":"Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma","volume":"22","author":"Lance","year":"2011","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib77","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","article-title":"Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Kooby","year":"2010","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.cld.2020.07.011_bib79","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib80","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib81","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2020.07.011_bib82","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","article-title":"A\u00a0comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization","volume":"9","author":"Lewandowski","year":"2009","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib83","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib84","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.26947","article-title":"Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization","volume":"59","author":"Garlipp","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","article-title":"Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization","volume":"79","author":"Riaz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","article-title":"Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study","volume":"28","author":"Padia","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","article-title":"Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma","volume":"29","author":"Biederman","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib88","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.cld.2020.07.011_bib89","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2020.07.011_bib90","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","article-title":"Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept","volume":"40","author":"Garin","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.cld.2020.07.011_bib91","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/liv.13220","article-title":"High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization","volume":"37","author":"Garin","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2020.07.011_bib92","doi-asserted-by":"crossref","unstructured":"Gari E. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01). Journal of Clinical Oncology 38(4_suppl):516.","DOI":"10.1200\/JCO.2020.38.4_suppl.516"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib93","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jvir.2018.10.016","article-title":"Same-day yttrium-90 radioembolization: feasibility with resin microspheres","volume":"30","author":"Li","year":"2019","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"4_suppl","key":"10.1016\/j.cld.2020.07.011_bib94","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2017.35.4_suppl.344","article-title":"Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial","volume":"35","author":"Finn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib95","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"18","key":"10.1016\/j.cld.2020.07.011_bib96","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/cncr.32206","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series","volume":"125","author":"Kambhampati","year":"2019","journal-title":"Cancer"},{"issue":"4_suppl","key":"10.1016\/j.cld.2020.07.011_bib97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2019.37.4_suppl.327","article-title":"Checkmate-040: nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status","volume":"37","author":"Kudo","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.cld.2020.07.011_bib98","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000343875","article-title":"JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan","volume":"3","author":"Kudo","year":"2014","journal-title":"Liver Cancer"},{"issue":"15_suppl","key":"10.1016\/j.cld.2020.07.011_bib99","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","article-title":"Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis","volume":"36","author":"Peck-Radosavljevic","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000480208","article-title":"Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2","volume":"35","author":"Arizumi","year":"2017","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.cld.2020.07.011_bib101","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","article-title":"Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"87","author":"Ogasawara","year":"2014","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.cld.2020.07.011_bib102","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000367743","article-title":"Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma","volume":"4","author":"Arizumi","year":"2015","journal-title":"Liver Cancer"},{"issue":"12","key":"10.1016\/j.cld.2020.07.011_bib103","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-016-1204-2","article-title":"Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON","volume":"51","author":"Kudo","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib104","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000495944","article-title":"Prediction of prognosis of intermediate-stage HCC patients: validation of the tumor marker score in a nationwide database in Japan","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000502905","article-title":"A\u00a0new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib106","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000494844","article-title":"Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients","volume":"8","author":"Hiraoka","year":"2019","journal-title":"Liver Cancer"},{"issue":"Suppl","key":"10.1016\/j.cld.2020.07.011_bib107","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/BF00647229","article-title":"Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy","volume":"23","author":"Kojiro","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4_suppl","key":"10.1016\/j.cld.2020.07.011_bib108","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2019.37.4_suppl.364","article-title":"A\u00a0nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan","volume":"37","author":"Tsuchiya","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cld.2020.07.011_bib109","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jamcollsurg.2016.12.020","article-title":"Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions","volume":"224","author":"Chapman","year":"2017","journal-title":"J\u00a0Am Coll Surg"},{"issue":"5","key":"10.1016\/j.cld.2020.07.011_bib110","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","article-title":"Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial","volume":"4","author":"Yoon","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.cld.2020.07.011_bib111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/lt.24977","article-title":"Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)","volume":"24","author":"Llovet","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2020.07.011_bib112","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12885-015-1373-z","article-title":"Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial","volume":"15","author":"Hoffmann","year":"2015","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2020.07.011_bib113","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000481245","article-title":"Immuno-oncology in hepatocellular carcinoma: 2017 update","volume":"93","author":"Kudo","year":"2017","journal-title":"Oncology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326120300623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326120300623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:57:33Z","timestamp":1761069453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326120300623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1089326120300623"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2020.07.011","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locoregional Therapies for Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2020.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}